Marginal zone lymphoma Clinical Trials
Recruiting marginal zone lymphoma studies with sites across the US, sourced from ClinicalTrials.gov and refreshed daily. Free to join — find one near you below.
Clinical trials study new ways to prevent, detect, or treat marginal zone lymphoma. Joining one can give you access to investigational treatments and close monitoring by a specialist research team — at no cost — while helping advance care for others. Below are recruiting marginal zone lymphoma studies with sites across the US; use the location tools to find ones near you.
What to expect
- Screening first. The study team reviews your eligibility before anything else — there's no obligation to continue.
- Informed consent. You'll get a full explanation of the study, its potential risks and benefits, and can withdraw at any time.
- No cost to you. Study visits, tests, and the investigational treatment are covered; many studies reimburse travel.
Recruiting marginal zone lymphoma trials
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Atrial Fibrillation Among Patients With Hematologic Malignancies on Tyrosine Kinase Inhibitor Therapy
Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL
Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma
Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
64Cu-LLP2A for Imaging Hematologic Malignancies
Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Epco, Zanu, Ritux for R/R FL or MZL
SynKIR-310 for Relapsed/Refractory B-NHL
CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas
Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma
Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE)
Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas
Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)
Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy
Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.
A Cohort Study in Newly Diagnosed MZL
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)
Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Allo HSCT Using RIC and PTCy for Hematological Diseases
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Marginal zone lymphoma clinical trials — common questions
Are marginal zone lymphoma clinical trials free to join?
Yes. Participating in a marginal zone lymphoma clinical trial is free — study-related visits, tests, and the investigational treatment are provided at no cost to you. Many studies also reimburse travel and time. You never pay to take part.
Who can join a marginal zone lymphoma clinical trial?
Each marginal zone lymphoma study sets its own eligibility criteria — typically based on age, medical history, current treatments, and overall health. Every trial listed here shows its criteria, and the study team confirms your eligibility before enrollment. You can review and apply to any that look like a fit.
How do I find a marginal zone lymphoma trial near me?
Use the location controls above. We'll show recruiting marginal zone lymphoma trials with sites near you, sorted by distance. You can widen the radius or share your exact location for the closest matches.
How many marginal zone lymphoma trials are recruiting right now?
We're currently tracking roughly 33 recruiting marginal zone lymphoma trials with US sites, sourced from ClinicalTrials.gov and refreshed daily.
Looking for a specific location? Browse trials by city and state.